NCT04319224View on ClinicalTrials.gov

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

January 3, 2023

Study Completion Date

January 3, 2023

Conditions
Cancer
Interventions
DRUG

Vopratelimab

Specified dose on specified days

DRUG

Ipilimumab

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

Trial Locations (3)

22908

University of Virginia Health Systems, Charlottesville

63110

Washington University School of Medicine, St Louis

77030

The University of Texas - MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Jounce Therapeutics, Inc.

INDUSTRY